Accreditation Information
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists engaged in the care of patients with cancer.
Learning Objectives
- Evaluate the safety and efficacy of current and emerging treatment strategies that are being investigated for patients with solid tumors, including thoracic, breast, head and neck, cutaneous, gynecologic, brain, gastrointestinal, and genitourinary cancers
- Assess the results of recently presented data of currently approved and emerging therapies aimed at improving the outcomes for patients with hematologic malignancies, including patients with B-cell and T-cell lymphomas, chronic and acute leukemias, and multiple myeloma
- Compare and contrast strategies for integrating novel agents into the treatment armamentarium for patients with hematologic and solid tumors in order to maximize the outcomes of patients
- Develop approaches that will lead to increased patient and clinician participation in clinical trials in order to address current unmet clinical needs faced by patients with cancer
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 18 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through Partner’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving Partners permission to use this information/data to report your participation to these Boards JA-PARS.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
|
Faculty
|
Conflicts of Interest
| |
|---|---|---|
|
Ahmed, Shahid S., MBBS
|
Has no relevant financial relationships
| |
|
Alese, Olatunji B., MD, FASCO
|
Consultant, Advisor, Speaker: AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Cartography Biosciences, Inc., Civala, Cue Biopharma, Inc., Exelixis, Ipsen Pharmaceuticals, Loxo Oncology, Natera, Revolution Medicines, Taiho Oncology, Takeda Pharmaceutical Company Researcher: Arcus Biosciences, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cue Biopharma, Inc., GSK, Inhibitex, Inc., Ipsen Pharmaceuticals, Loxo Lilly Oncology, Merck, Taiho Oncology, Xencor, Inc. Independent Data Monitoring Committee: Compass Therapeutics, Inc.
| |
|
Anderson, Kenneth C., MD
|
Consultant, Advisor, Speaker: C4 Therapeutics, Dynamic Cell Therapies, Genentech (Roche), GSK, Predicta, Starton, Tolremo, Window
| |
|
Arciero, Cletus A., MD, FACS
|
Has no relevant financial relationships
| |
|
Arellano, Martha L., MD
|
Has no relevant financial relationships
| |
|
Baliga, Sujith, MD
|
| |
|
Berchuck, Jacob E., MD
|
Consultant, Advisor, Speaker: Genome Medical, Guardant Health, Musculo, Natera, Oncotect, Precede Biosciences, Tracer Biotechnologies
| |
|
Bhave, Manali, MD
|
Consultant, Advisor, Speaker: AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis
| |
|
Bou Zerdan, Maroun, MD
|
Has no relevant financial relationships
| |
|
Brown, Jacquelin, MD
|
Consultant, Advisor, Speaker: AstraZeneca, Pfizer Researcher: Astellas, Duality Biologics, EVOLVEIMMUNE, Medicenna, Merck, Novartis, Pliant Therapeutics
| |
|
Buchwald, Zachary S., MD, PhD
|
Researcher: Alpha Tau
| |
|
Cardona, Kenneth, MD, FACS
|
Has no relevant financial relationships
| |
|
Carlisle, Jennifer W., MD
|
Consultant, Advisor, Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genentech, Gilead, Immunity Bio Researcher: Chipscreen
| |
|
Carthon, Bradley C., MD, PhD
|
Has no relevant financial relationships
| |
|
Chang, Andres, MD, PhD
|
Consultant, Advisor, Speaker: BeOne, BMS Researcher: AbbVie
| |
|
Ciuro, Jordan, MD
|
Consultant, Advisor, Speaker: Johnson & Johnson
| |
|
Cohen, Jonathan B., MD, MS
|
Consultant, Advisor, Speaker: AstraZeneca, ADCT, BeOne, Incyte Researcher: AstraZeneca, ADCT, BeOne Celgene, Genetech, Lilly, Novartis, Nurix, Takeda Data Monitoring Committee: Merck
|
|
|
Donovan, Laura, MD
|
Has no relevant financial relationships
| |
|
Emiloju, Oluwadunni, MBBS, MS
|
Consultant, Advisor, Speaker: BMS, Revolution Medicine Researcher: Coherus, Genentech Stock Options: Telix
| |
|
Gadgeel, Shirish M., MD
|
Consultant, Advisor, Speaker: AbbVie, AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech (Roche), Gilead Sciences, GSK, Johnson & Johnson, Lilly, MBrace, Pfizer, Regeneron, Summit Therapeutics Data Safety Monitoring Board Member: AstraZeneca
| |
|
Gandhi, Shipra, MD, MS
|
Consultant, Advisor, Speaker: Aptitude Health, AstraZeneca, Genentech (Stemline Therapeutics), Hologic, MedPage Today, MJH Life Sciences, PeerView, Roche
| |
|
Gbolahan, Olumide B., MBBS, MSc
|
Consultant, Advisor, Speaker: AstraZeneca, Ipsen, Revolution Medicine
| |
|
Halperin, Daniel M., MD
|
Consultant, Advisor, Speaker: AbbVie, Exelixis, Lantheus, Sanofi (Sanofi-Aventis), TerSera, Wren Laboratories Researcher: Chimeric Therapeutics, Crinetics, Novartis
| |
|
Hannan, Lindsay M., MD, MSc
|
Has no relevant financial relationships
| |
|
Hochman, Michael J., MD
|
Consultant, Advisor, Speaker: Blueprint Medicines, Clinical Care Targeted Communications Group LLC/ American Journal of Managed Care, Johnson & Johnson, OncLive/Oncology Specialty Group, Rigel Pharmaceuticals
| |
|
Hunter, Anthony M., MD
|
Consultant, Advisor, Speaker: BMS, Cycle Pharmaceuticals, Geron, Incyte, Karyopharm Therapeutics, Merck, Novartis, PharmaEssentia, Sobi
| |
|
Iyengar, Neil M., MD
|
Consultant, Advisor, Speaker: Amneal Pharmaceuticals, Arvinas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Genentech (Roche), Gilead Sciences, Novartis, Pfizer
| |
|
Jagsi, Reshma, MD, DPhil
|
National Medical Advisor Panelist: Blue Cross Blue Shield
| |
|
Joseph, Nisha, MD
|
Consultant, Advisor, Speaker: Bristol Myers Squibb, CellCentriq, Genentech, GSK, Johnson & Johnson Oncology, Pfizer Oncology, Regeneron
| |
|
Kaka, Azeem S., MD
|
Has no relevant financial relationships
| |
|
Kalinsky, Kevin, MD, MS, FASCO
|
Consultant, Advisor, Speaker: AstraZeneca, Bicycle Therapeutics, bioTheranostics, Daiichi Sankyo, Eli Lilly, Genentech (Roche), Gilead Sciences, Jazz Pharmaceuticals, Menarini Silicon Biosystems, Merck, Mersana Therapeutics, Myovant Sciences, Novartis, Pfizer, ProteinQure, Puma Biotechnology, RayzeBio, Regor Therapeutics, Relay Therapeutics, Seagen, Seattle Genetics (Seagen)
| |
|
Kantarjian, Hagop M., MD
|
Consultant, Advisor, Speaker: AbbVie, Amgen, Ascentage Pharma, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen TargetRx, Stemline Therapeutics, Takeda Pharmaceutical Company Researcher: AbbVie, Amgen, Ascentage, BMS, Daiichi Sankyo, Immunogen, Novartis
| |
|
Kaufman, Johnathon L., MD
|
Consultant, Advisor, Speaker: BMS, Genentech, Kite Pharma, Sanofi Researcher: AbbVie, Amgen, BeOne, BMS, Genentech, GSK, Heidelberg Pharma AB, Janssen, Kite Pharma, Nexcella, Pfizer
| |
|
Khuri, Fadlo R., MD
|
Has no relevant financial relationships
| |
|
King, Tari A., MD, FACS, FSSO, FASCO
|
Consultant, Advisor, Speaker: Ataraxis AI, Daiichi Sankyo, Exact Sciences, Veracyte
| |
|
Kodia, Karishma, MD
|
Has no relevant financial relationships
| |
|
Koff, Jean L., MD, MS
|
Consultant, Advisor, Speaker : AbbVie, ADC Therapeutics, BeOne, Incyte, Pierre Fabre Researcher: Regeneron
| |
|
Langston, Amelia A., MD
|
Researcher: Acepodia, Autolus, BMS, Iovance, Miltenyi Biomedicine, Novartis
| |
|
Leal, Ticiana, MD
|
Consultant, Advisor, Speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst Pharmaceuticals, Genentech, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Molecular Therapeutics, Novocure, Nuvation Bio, Summit Therapeutics, Synthekine, Verastem Researcher: Onco4
| |
|
Lonial, Sagar, MD, FACP, FASCO
|
| |
|
Lowe, Michael C., MD, MA
|
Consultant, Advisor, Speaker: Merck, Regeneron, Replimune, Philogen
| |
|
Mamdani, Hirva, MD
|
Consultant, Advisor, Speaker: AstraZeneca, BMS, Daiichi Sankyo Researcher: AstraZeneca
| |
|
Meisel, Jane Lowe, MD, FASCO
|
Consultant, Advisor, Speaker: AstraZeneca, Eli Lilly, Novartis, Olema, Pfizer, Sermonix Researcher: AstraZeneca, Olema, Sermonix
| |
|
Mina, Roberto, MD
|
Consultant, Advisor, Speaker: GSK, Johnson & Johnson, Pfizer, Roche, Sanofi
| |
|
Modesitt, Susan C., MD, FACOG, FACS
|
Consultant, Advisor, Speaker: Curio Science, Elsevier Researcher: Corcept Therapeutics, Gilead Sciences, GOG Foundation, ImmunoGen
| |
|
Modi, Dipenkumar, MD
|
Consultant, Advisor, Speaker: ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, DAVA Oncology (spouse), Genmab, Ideology (spouse), Incyte, Regeneron
| |
|
Nduom, Edjah K., MD, FAANS
|
Consultant, Advisor, Speaker: Servier Pharmaceuticals
| |
|
Nooka, Ajay K., MD, MPH, FACP
|
Consultant, Advisor, Speaker: AstraZeneca, Blue Earth Diagnostics, Cellectar Biosciences, GSK, Janssen, Kite Therapeutics, ONK Therapeutics, OPNA, Pfizer, Perceptive Informatics, LLC, Premier Research, Sanofi, Sebia
| |
|
O'Brien, Susan M., MD
|
Consultant, Advisor, Speaker: AbbVie, AstraZeneca, Autolus, BeiGene, Ltd., Bristol Myers Squibb, Eli Lilly and Company, Epizyme, Janssen Oncology, Johnson & Johnson, Pharmacyclics Researcher: Alliance, Caribou Biosciences, Inc., Nurix Therapeutics, Regeneron
| |
|
Oluloro, Ann, MD, MPH, FACOG
|
Has no relevant financial relationships
| |
|
Ozer, Byram, MD, PhD
|
Researcher: GCAR, Nuvation Bio
| |
|
Pan, Kelsey, MD, MPH
|
Consultant, Advisor, Speaker: Johnson & Johnson
| |
|
Papadantonakis, Nikolaos, MD, PhD, MSc
|
Consultant, Advisor, Speaker: Geron Researcher: AGIOS, Curis, Novartis
| |
|
Parikh, Ravi B., MD, MPP, FACP
|
Consultant, Advisor, Speaker: ConcertAI, Counsel Health, Main Street Health, Mendel.ai, Onc.ai, Optinosis, Thyme Care
| |
|
Ramalingam, Suresh S., MD, FACP, FASCO
|
Researcher: Amgen, AstraZeneca, BMS, Merck, Pfizer
| |
|
Saba, Nabil F., MD, FACP
|
Consultant, Advisor, Speaker: AbbVie, Adagene, Astex Pharmaceuticals, Aveo Pharmaceuticals, BioNTech, BMS, Coherus BioSciences, CUE Biopharma, Exelixis, Faron Pharmaceuticals, Flamingo Therapeutics, Fulgent Genetics, GSK, Imugene, Infinity Pharmaceuticals, Inovio Pharmaceuticals, Johnson & Johnson, Kura Oncology, Merck, Merch KGaA (EMD Serono), Merus, Nanobiotix, Pfizer, Reddy Laboratories, Seagan, Summit Therapeutics, Surface Oncology, Taiho Oncology, UroGen Pharma, Vaccinex Researcher: Medscape, OncLive, UpToDate, Springer
| |
|
Scalici, Jennifer M., MD
|
Consultant, Advisor, Speaker: Absco Therapeutics, Kiyatec, Pfizer
| |
|
Schneider, Michael A., MD, PhD
|
Stock Options: Guardant Health
| |
|
Starbuck, Kristen D., MD
|
Has no relevant financial relationships
| |
|
Steuer, Conor E., MD
|
Consultant, Advisor, Speaker: BMS, Boehringer Ingelheim, Daiichi Sankyo, Genentech, Merck, Novocure
| |
|
Tfaily, Mohamed-Ali, MD
|
Has no relevant financial relationships
| |
|
Torres, Mylin A., MD
|
Consultant, Advisor, Speaker: Varian Researcher: Pfizer
| |
|
Vale, Colin A., MD
|
Consultant, Advisor, Speaker: Geron Corporation, Syndax Pharmaceuticals
| |
|
Wilson, Melissa A., MD, PhD
|
Consultant, Advisor, Speaker : BMS, Regeneron
| |
|
Wilson, Nathaniel R., MD
|
Has no relevant financial relationships
|
Instructions for Credit
To receive CE credit, learners must follow these steps:
1. Link for activity evaluation coming soon
2. Complete the activity evaluation
3. Upon completion of all evaluation questions, your credit will be made available for download immediately.